Skip to main content
SpringerLink
Log in

Erectile dysfunction: symptom or disease?

  • Review Article
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Erectile dysfunction (ED) has been defined by the National Institute of Health (NIH) as the inability to achieve and/or to maintain an erection for a sufficiently long period of time so as to permit satisfactory sexual intercourse. ED affects millions of men throughout the world and could have a negative influence on the individual’s well-being as well as on the quality of life of affected subjects. Discordant data have been reported on ED epidemiology with prevalence ranging from 12% to 52%, probably depending on the different criteria utilized in the different studies for patient selection. ED is a symptom, sometimes the first, of different pathological conditions. In 15.7% of 45-yr-old patients with vascular ED a dynamic ergometric test has shown electrocardiographic alterations in the absence of any cardiac symptom. In 15% of the patients with ED, high fasting glucose plasma levels are discovered for the first time and in patients with ED and normal fasting glucose plasma levels the prevalence of undiagnosed diabetes mellitus is 12.1% after an oral glucose tolerance test (OGTT). The different risk factors are often additive in the possible development of systemic vasculopathy, neuropathy and ED. ED, underestimated in clinical practice due to archaic prejudice which hinders the patient in spontaneously revealing the problem and the physicians in investigating it, can mark the point where evaluation and prevention of important diseases (such as diabetes, arterial hypertension, atherosclerosis) hitherto unknown by the patients, can begin. The physicians’ cultural baggage must include the ability to identify the pathology that can determine ED and the ability to program a specific diagnostic workup. In this paper the different specialists involved in ED diagnosis agreed that a clinical approach which allows the identification of systemic pathologies contributing to the development of ED constitutes an improvement in disease prognosis and may either induce a spontaneous reduction of ED or facilitate its specific treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. NIH Consensus Development Panel on Impotence. NIH Consensus Conference: impotence. JAMA 1993, 270: 83–90.

    Google Scholar 

  2. Wagner G, Fugl-Meyer AR. Impact of erectile dysfunction on quality of life: patient and partner perspectives. Int J Imp Res 2000, Suppl 4: S144–6.

    Google Scholar 

  3. Spera G, Mariani S, Spera E, Pili M. La disfunzione erettile come sintomo di patologie internistiche: nuove frontiere terapeutiche. Atti del 103° Congresso Nazionale della Società Italiana di Medicina Interna. Milano, 19–22 novembre 2002. Ann Ital Med Int. 2002, 17: 33S–42S.

    Google Scholar 

  4. DeWire DM. Evaluation and treatment of erectile dysfunction. Am Fam Physician. 1995, 53: 2101–07.

    Google Scholar 

  5. Deutsch S, Sherman L. Previously unrecognized diabetes mellitus in sexually impotent men. JAMA 1980, 244: 2430–2.

    CAS  PubMed  Google Scholar 

  6. Sairam K, McNicholas TA. Prevalence of undiagnosed diabetes mellitus in male erectile dysfunction. BJU 2001, 88: 68–71.

    CAS  Google Scholar 

  7. Soo Woong K. Potential predictors of asymptomatic ischemic heart disease in patients with vasculogenic erectile dysfunction. Urol. 2001, 58: 441–5.

    Google Scholar 

  8. Kawanishi Y, Sogou T. Screening of ischemic heart disease with cavernous artery blood flow in erectile dysfunction patients. Int J Impot Res 2001, 13: 100–3.

    CAS  PubMed  Google Scholar 

  9. Billups K, Friedrich S. Assessment of fasting lipid panels and Doppler ultrasound testing in men presenting with erectile dysfunction and no other medical problems. 95th Annual Meeting of the American Urological Association. 2000, Atlanta, GA. Abstract 655.

    Google Scholar 

  10. Aversa A, Isidori AM, Lenzi A, Spera G, Fabbri A. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf), 2003, 58: 632–8.

    CAS  Google Scholar 

  11. Wespes E, Amar E, Hatzichristou D, Montorsi F, Pryor J, Vardi J. Guidelines on Erectile Dysfunction. E Urol 2002, 41: 1–5.

    Google Scholar 

  12. Canadian Urological Association Guidelines Committee. Erectile dysfunction practice guidelines. Can J Urol 2002, 9: 1583–87.

    Google Scholar 

  13. Furlow WL. Prevalence of impotence in the United States. Med Aspects Hum Sex 1985, 19: 13–16.

    Google Scholar 

  14. Kinsey AC, Martin CE. Sexual Behaviour in Human Males. Philadelphia, Saunders, 1948.

    Google Scholar 

  15. Slag MF, Morley JE, Elson MK, et al. Impotence in medical clinic outpatients. JAMA 1983, 249: 1736–42.

    CAS  PubMed  Google Scholar 

  16. Diokno AC, Herzog AR. Sexual function in the elderly. Arch Intern Med 1990, 150: 197–200.

    CAS  PubMed  Google Scholar 

  17. Feldman HA, Goldstein I, et al. Impotence and its medica and psychological correlates: results of the Massachusetts Male Ageing Study. J Urol 1994, 151: 54–61.

    CAS  PubMed  Google Scholar 

  18. Parazzini F, Menchini Fabris F, Bortolotti A, et al. Frequency and determinants of erectile dysfunction in Italy. Eur Urol 2000, 37: 43–49.

    CAS  PubMed  Google Scholar 

  19. Vallancien G, Emberton M, Harving N, Jeroen R, van Moorselaar A. Sexual dysfunction in 1,274 european men suffering from lower urinary tract symptoms. J Urol 2003, 169: 2257–61.

    PubMed  Google Scholar 

  20. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the “Cologne Male Survey”. Int J Impot Res 2000, 12: 305–11.

    CAS  PubMed  Google Scholar 

  21. Wei M, Macera CA, Davis DR. Total cholesterol and high density lipoprotein cholesterol as important predictors of erectile dysfunction. Am J Epidemiol 1994, 140: 930–7.

    CAS  PubMed  Google Scholar 

  22. Tengs TO, Osgood ND. The link between smoking and impotence. Two decades of evidence. Prev Med 2001, 32: 447–52.

    CAS  PubMed  Google Scholar 

  23. McCulloch DK, Campbell IW, Wu FC, Prescott RJ, Clarke BF. The prevalence of diabetic impotence. Diabetologia 1980, 18: 279–83.

    CAS  PubMed  Google Scholar 

  24. Rubin A. Impotence and diabetes mellitus. JAMA 1958; 168: 496.

    Google Scholar 

  25. Brunner GA, Pieber TR, Schattenberg S, et al. Erectile dysfunction in patients with type I diabetes mellitus. Wien Med Wochenschr 1995, 145: 584–6.

    CAS  PubMed  Google Scholar 

  26. Klein R, Lee KE, Moss SE, Cruickshanks KJ. Prevalence of self-reported erectile dysfunction in people with long-term IDDM. Diabetes Care 1996, 19: 135–41.

    CAS  PubMed  Google Scholar 

  27. Johannes CB, Feldman HA, Araujo AB, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol 2000, 163: 460–3.

    CAS  PubMed  Google Scholar 

  28. Fedele D, Coscelli C, Forti G, et al. Incidence of erectile dysfunction in italian men with diabetes. J Urol 2001, 166: 1368–71.

    CAS  PubMed  Google Scholar 

  29. Fugl-Meyer AR, Fugl-Meyer KS, Lundberg PO. Sexual rehabilitation. In: Frommelt P. Grotzbach eds. Neuro-rehabilitation. Oxford: Blackwell. 1999, 370–88.

    Google Scholar 

  30. Lundberg PO, Ertekin C, Ghezzi A, Swash M, Vodusek D. Neurosexology. Eur J Neurol 2001, 8 (Suppl. 3): 2–24.

    Google Scholar 

  31. Lue TF. Erectile dysfunction. N Engl J Med 2000, 342: 1802–13.

    CAS  PubMed  Google Scholar 

  32. Buvat J, Lemaire A. Endocrine screening in 1022 men with erectile dysfunction: clinical significance and cost-effective strategy. J Urol 1997, 158: 1768–9.

    Google Scholar 

  33. Johri AM, Heaton JP, Morales A. Severe erectile dysfunction is a marker for hyperprolactinemia. Int J Impot Res 2001, 13: 176–82.

    CAS  PubMed  Google Scholar 

  34. Derby CA, Barbour MM, Hume AL, McKinlay JB. Drug therapy and prevalence of erectile dysfunction in the Massachusetts Male Aging Study cohort. Pharmacotherapy 2001, 21: 676–83.

    CAS  PubMed  Google Scholar 

  35. Siegel T, Moul JW, Spevak M, Alvord WG, Costabile RA. The development of erectile dysfunction in men treated for prostate cancer. J Urol 2001, 165: 430–35.

    CAS  PubMed  Google Scholar 

  36. Aytac IA, Araujo AB, Johannes CB, Kleinman KP, McKinlay JB. Socioeconomic factors and incidence of erectile dysfunction: findings of the longitudinal Massachusetts Male Aging Study. Soc Sci Med 2000, 51: 771–78.

    CAS  PubMed  Google Scholar 

  37. Marumo K, Murai M. Aging and erectile dysfunction: the role of aging and concomitant chronic illness. Int J Urol 2001, 8:S50–57.

    CAS  PubMed  Google Scholar 

  38. Aizenberg D, Zemishlany Z, Dorfman-Etrog P, Weizman A. Sexual dysfunction in male schizophrenic patients. J Clin Psychiatry 1995, 56: 137–41.

    CAS  PubMed  Google Scholar 

  39. Aversa A, Rocchietti-March M, Caprio M, et al. Pharmacology of male sexual dysfunction. Minerva Endocrinol 1998, 23: 17–25.

    CAS  PubMed  Google Scholar 

  40. Bradford JMW. Treatment of sexual offenders with cyproterone acetate. In: Sitsen JMA ed. Handbook of sexology. Amsterdam: Elsevier 1988, 526–36.

    Google Scholar 

  41. Burchardt M, Burchardt T, Baer L, et al. Hypertension is associated with severe erectile dysfunction. J Urol 2000, 164: 1189–91.

    Google Scholar 

  42. De Rose AF, Carmignani G, Corbu C, et al. Observational multicentric trial performed with doxazosin: evaluation of sexual effects on patients with diagnosed benign prostatic hyperplasia. Urol Int 2002, 68: 95–8.

    PubMed  Google Scholar 

  43. Donahue JL, Lowenthal DT. Androgens, anabolic-androgenic steroids and inhibitors. Am J Ther 2000, 7: 365–73.

    CAS  PubMed  Google Scholar 

  44. Epstein RJ, Allen RC, Lunde MW. Organic impotence associated with carbonic anhydrase inhibitor therapy for glaucoma. Ann Ophthalmol 1987, 19: 48–50.

    CAS  PubMed  Google Scholar 

  45. Fava M, Rankin M. Sexual functioning and SSRIs. J Clin Psychiatry 2002, 63 (Suppl 59): 13–6.

    PubMed  Google Scholar 

  46. Fogari R, Zoppi A. Effects of antihypertensive therapy on sexual activity in hypertensive men. Curr Hypertens Rep 2002, 4: 202–10.

    PubMed  Google Scholar 

  47. Grimm RH, Grandis GA, Prineas RJ, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of mild hypertension Study. Hypertension 1997, 29: 8–17.

    CAS  PubMed  Google Scholar 

  48. Husain AM, Carwile ST, Miller PP, Radtke RA. Improved sexual function in three man taking lamotrigine for epilepsy. South Med J 2000, 93: 335–6.

    CAS  PubMed  Google Scholar 

  49. Jensen J, Lendorf A, Stimpel H, Frost J, Ibsen H, Rosenkilde P. The prevalence and etiology of impotence in 101 male hypertensive outpatients. Am J Hypertens 1999, 12: 271–5.

    CAS  PubMed  Google Scholar 

  50. Keene LC, Davies PH. Drug-related erectile dysfunction. Adverse Drug React Toxicol Rev 1999, 18: 5–24.

    CAS  PubMed  Google Scholar 

  51. Khan MA, Morgan RJ, Mikhailidis DP. The choice of antihypertensive drugs in patients with erectile dysfunction. Curr Med Res Opin 2002, 18: 103–7.

    PubMed  Google Scholar 

  52. Lambert MV. Seizures, hormones and sexuality. Seizure 2001, 10:319–40.

    CAS  PubMed  Google Scholar 

  53. Langford HG, Rockhold RW, Wassertheil-Smoller S, Oberman A, Davis BR, Blaufox MD. Effect of weight loss on thiazide produced erectile problems in men. Trans Am Clin Climatol Assoc 1989, 101: 190–4.

    Google Scholar 

  54. Listerri JL, Lozano Vidal JV, et al. CM. Sexual dysfunction in hypetensive patients treated with losartan. Am J Med Sci 2001, 321: 336–41.

    Google Scholar 

  55. Mari D. Andrologic problems and internal pathology in the elderly. Arch Ital Urol Androl 1993, 65: 507–10.

    CAS  PubMed  Google Scholar 

  56. Mikhailidis DP, Khan MA, Milionis HJ, Morgan RJ. The treatment of hypertension in patients with erectile dysfunction. Curr Med Res Opin 2000, 16 (Suppl 1): 31–6.

    Google Scholar 

  57. Muller SC, El-Damanhoury H, Ruth J, Lue TF. Hypertension and impotence. Eur Urol 1991, 19:29–34.

    CAS  PubMed  Google Scholar 

  58. Pillay VK. Some side effects of alfa-methyldopa. S Afr Med J 1976, 50: 625–6.

    CAS  PubMed  Google Scholar 

  59. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999, 21: 241–42.

    Google Scholar 

  60. Segraves RT. Sexual side effects of psychiatric drugs. Int J Psychiatry Med 1988, 18: 243–52.

    CAS  PubMed  Google Scholar 

  61. Weiss RJ. Effects of antihypertensive agents on sexual function. Am Fam Physician 1991, 44: 2075–82.

    CAS  PubMed  Google Scholar 

  62. Davis-Joseph B, Tiefer L, Melman A. Accuracy of the initial history and physical examination to establish the etiology of erectile dysfunction. Urology 1995, 45: 498–52.

    CAS  PubMed  Google Scholar 

  63. Speckens AM. Discrimination between psychogenic and organic erectile dysfunction. J Psychosom Res 1993, 37: 135.

    CAS  PubMed  Google Scholar 

  64. Tiefer L, Schuetz-Mueller D. Psycological issues in diagnosis and treatment of erectile disorders. Urol Clin North Am 1995, 22: 767–73.

    CAS  PubMed  Google Scholar 

  65. Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM. Development and evaluation of an abridge 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 1999, 11: 319–26.

    CAS  PubMed  Google Scholar 

  66. Akerman MD, D’Attilio JP. Sexual Dysfunction: a Neuro-Medical Approach. Armoni, NY: Futura Publishing Company, Inc. 1994, 229–44.

    Google Scholar 

  67. Petrone L, Mannucci E, Corona G, et al. Structured interview on erectile dysfunction (SIEDY): a new, multidimensional instrument for quantification of pathogenetic issues on erectile dysfunction. Int J Impot Res 2003 15: 210–20.

    CAS  PubMed  Google Scholar 

  68. Kandeel FR, Koussa V, Swerdloff R. Male sexual function and its disorders: physiology, pathophysiology, clinical investigation and treatment. Endocr Rev 2001, 22: 342–88.

    CAS  PubMed  Google Scholar 

  69. Levine LA. Diagnosis and treatment of erectile dysfunction. Am J Med 2000, 109: 3S–12S.

    PubMed  Google Scholar 

  70. The process of care consensus panel. Position paper: the process of care model for evaluation and treatment of erectile dysfunction. Int J Imp Res 1999, 11: 59–74.

    Google Scholar 

  71. Breda G, Breda G, Xausa D, et al. Nomogram for penile biothesiometry. Eur Urol 1991, 20: 67–9.

    CAS  PubMed  Google Scholar 

  72. Morales A, Heaton JP. Hormonal erectile dysfunction. Evaluation and management. Urol Clin North Am 2001, 28: 279–88.

    CAS  PubMed  Google Scholar 

  73. Vermeulen A, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999, 84: 3666–72.

    CAS  PubMed  Google Scholar 

  74. Johri AM, Morales A. Severe erectile dysfunction is a marker for hyperprolactinemia. Int J Impot Res 2001, 13: 176–82.

    CAS  PubMed  Google Scholar 

  75. Carani C, Marrama P. Prolactin and testosterone: their role in male sexual function. Int J Androl 1996, 19: 48–54.

    CAS  PubMed  Google Scholar 

  76. Bradley WE, Timm GW, Gallagher JM, Johnson BK. New method for continuous measurement of nocturnal penile tumescence and rigidity. Urology 1985, 26: 4–6.

    CAS  PubMed  Google Scholar 

  77. Levine L, Lenting EL. Use of nocturnal penile tumescence and rigidity in the evaluation of male erectile dysfunction. Urol Clin North Am 1995, 22: 775–88.

    CAS  PubMed  Google Scholar 

  78. Eardley I, Sethia K. Erectile Dysfunction — Current Investigation and management. London: Mosby-Wolfe. 1998.

    Google Scholar 

  79. Schiavi RC. The role of sleep laboratory in the evaluation of male erectile dysfunction. Mt Sinai J Med 1994, 61: 161–5.

    CAS  PubMed  Google Scholar 

  80. Krane RJ, Goldstein I, Saenz de Tejada I. Impotence. N Engl J Med 1989, 321: 1648–59.

    CAS  PubMed  Google Scholar 

  81. Mueller SC, Schild HH. Comparison of selective internal iliac pharmaco-angiography, penile brachial index and duplex sonography with pulsed Doppler analysis for the evaluation of vasculogenic (arteriogenic) impotence. J Urol 1990, 143: 928–32.

    CAS  PubMed  Google Scholar 

  82. Aitchison M, Aitchison J, Carter R. Is the penile brachial index a reproducible and useful measurement? Br J Urol 1990, 66: 202–4.

    CAS  PubMed  Google Scholar 

  83. Linet OI, Ogrinc FG. Efficacy and safety of intracavernousal alprostadil in men with erectile dysfunction. New Eng J Med 1996, 334: 873–7.

    CAS  PubMed  Google Scholar 

  84. Belgrano E, Savoca G. Disfunzione erettiva: Le linee guida della Consensus di Trieste. Milano: Ariete Salute Editore, 2001.

    Google Scholar 

  85. Aversa A, Rocchietti-March M, Isidori A, Fabbri A. Anxiety-induced failure in erectile response to intracorporea prostaglandin-E1 in non-organic male impotence: a new diagnostic approach. Int J Androl 1996, 19: 307–13.

    CAS  PubMed  Google Scholar 

  86. Pescatori E, Hatzichristou DG, Namburi S, Goldstein I. A positive intracavernous injection test implies a norma veno-occlusive but not necessarily normal arterial function: a haemodynamic study. J Urol 1994, 151: 1209–16.

    CAS  PubMed  Google Scholar 

  87. Aversa A, Isidori AM, Cerilli M, Frajese V, Fabbri A. Penile pharmacotesting in diagnosing male erectile dysfunction: evidence for a lack of accuracy and specificity. Int J Androl 2002, 25: 6–10.

    PubMed  Google Scholar 

  88. Lue TF, Hricak H, Marich KW, Tanagho EA. Vasculogenic impotence evaluated by high resolution ultrasonography and pulsed doppler spectrum analysis. Radiology 1985, 155: 777–81.

    CAS  PubMed  Google Scholar 

  89. Cormio L, Bettocchi C, Ricapito V, Zizzi V, Traficante A, Selvaggi FP. Resistance index as a prognostic factor for prolonged erection after penile dynamic colour Doppler ultrasonography. Eur Urol 1998, 33: 94–7.

    CAS  PubMed  Google Scholar 

  90. Aversa A, Isidori AM, De Martino MU, et al. Androgens and penile erection: evidence for a direct relationship between free testosterone and cavernous vasodilation in men with erectile dysfunction. Clin Endocrinol (Oxf) 2000, 53: 517–22.

    CAS  Google Scholar 

  91. Mancini M, Bartolini M, Maggi M, Innocenti P, Forti G. The presence of arterial anatomical variations can affect the results of duplex sonographic evaluation of penile vessels in impotent patients. J Urol 1996, 155: 1919–23.

    CAS  PubMed  Google Scholar 

  92. Cormio L, Nisen H, Ruutu M, Selvaggi FP. Etilefrine in the prevention of prolonged erection after diagnostic pharmacological stimulation. Ann Chir Gynaecol 1996, 85: 247–50.

    CAS  PubMed  Google Scholar 

  93. Slob AK, Cornelissen S, Dohle GR, Gijs L, van der Werff ten Bosch JJ. The limited practical value of color Doppler sonography in the differential diagnosis of men with erectile dysfunction. Int J Impot Res 2002, 14: 201–3.

    CAS  PubMed  Google Scholar 

  94. Montorsi F, Guazzoni G, Bergamaschi F, et al. Vascular abnormalities in Peyronie’s disease: the role of color doppler sonography. J Urol 1994, 151: 373–5.

    CAS  PubMed  Google Scholar 

  95. Delcour C, Struyven J. Techniques for performing cavernosometry and cavernosography. Cardiovasc Intervent Radiol 1988, 11: 211–7.

    CAS  PubMed  Google Scholar 

  96. Montague DK, Lakin MM. False diagnoses of venous leak impotence. J Urol 1992, 148:148–9.

    CAS  PubMed  Google Scholar 

  97. Petrou S, Lewis RW. Management of corporeal veno-occlusive dysfunction. Urol Int 1992, 49: 48–55.

    CAS  PubMed  Google Scholar 

  98. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev 1995, 75: 191–236.

    CAS  PubMed  Google Scholar 

  99. Giuliano FA, Jardin A. Neural control of penile erection. Urol Clin North Am 1995, 138: 747–66.

    Google Scholar 

  100. Padma-Nathan H. Neurologic evaluation of erectile dysfunction. Urol Clin North Am 1988, 15: 77–80.

    CAS  PubMed  Google Scholar 

  101. Lin JT, Bradley WE. Penile neuropathy in insulin-dependent diabetes mellitus. J Urol 1985, 133: 213–5.

    CAS  PubMed  Google Scholar 

  102. Espino P. Neurogenic impotence: diagnostic value of nerve conduction studies, bulbocavernosus reflex and heart rate variability. Electromyogr Clin Neurophysiol 1994, 34: 373–6.

    CAS  PubMed  Google Scholar 

  103. Bemelmans BL, Debruyne FM. Penile sensory disorders in erectile dysfunction: results of a comprehensive neuro-urophysiological diagnostic evaluation in 123 patients. J Urol 1991, 146: 742–77.

    Google Scholar 

  104. Nikiforidis G, Barbalias G. Reduced variance of latencies in pudendal evoked potentials after normalization for body height. Neurourol Urodyn 1995, 14:239–51.

    CAS  PubMed  Google Scholar 

  105. Goldstein I. Neurologic impotence. In: Krane RJ, Siroky MVB, Goldstein I eds. Male sexual dysfunction. Boston: Little, Brown and Co. 1983, 193–201.

    Google Scholar 

  106. Campese VM, Massary SG. Autonomic nervous system dysfunction and impotence in uremia. Am J Nephrol 1982, 2: 140–3.

    CAS  PubMed  Google Scholar 

  107. Brune S, Lucking CH. Cardiovascular parameters: sensitivity to detect autonomic dysfunction and influence of age and sex in normal subjects. Clin Autonom Res 1996, 6: 3–15.

    Google Scholar 

  108. Diemond WL, Meuleman EJ. Neurological testing in erectile dysfunction. J Androl 1997, 4: 345–50.

    Google Scholar 

  109. Derouet H, Ziegler M. Penile sympathetic skin response in erectile dysfunction. Eur Urol 1995, 28: 314–9.

    CAS  PubMed  Google Scholar 

  110. Gutrecht JA. Sympathetic skin response. J Clin Neurophysiol 1994, 11: 519–24.

    CAS  PubMed  Google Scholar 

  111. Beck R, Fowler CJ. Neurophysiological testing in erectile dysfunction. In: Carson C, Kirby R, Goldstein I eds. Textbook of erectile dysfunction. Oxford: Isis. 1999, 257–66.

    Google Scholar 

  112. Kloner RA, Speakman M. Erectile dysfunction and atherosclerosis. Curr Atheroscler Rep 2002, 4: 397–401.

    PubMed  Google Scholar 

  113. Wabrek AJ, Burchell RC. Male sexual dysfunction associated with coronary heart disease. Arch Sex Behav 1980, 9: 69–75.

    CAS  PubMed  Google Scholar 

  114. Gundle MJ, Tate S, et al. Psychological outcome after aortocoronary artery surgery. Am J Psychiatry 1980, 137: 1591–4.

    CAS  PubMed  Google Scholar 

  115. Ruzbarski V, Michal V. Morphologic changes in the arterial bed of the penis with ageing: relationship to the pathogenesis of impotence. Invest Urol 1977, 15: 194–9.

    Google Scholar 

  116. Agarwal A, Jain DC. Male sexual dysfunction after stroke. J Assoc Physicians India 1989, 37: 505–7.

    CAS  PubMed  Google Scholar 

  117. Chalmers J, MacMahon S, Mancia G, et al. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. Clin Exp Hypertens 1999, 21: 1009–60.

    CAS  PubMed  Google Scholar 

  118. Harris MI. Undiagnosed NIDDM: clinical and public health issues. Diabetes Care 1993, 16: 642–52.

    CAS  PubMed  Google Scholar 

  119. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4–7 yr. before clinical diagnosis. Diabetes Care 1993, 15: 15–9.

    Google Scholar 

  120. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352: 837–53.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Male Gamete Cryopreservation, Department of Medical and Surgical Sciences, University of Padua, Via Ospedale 5, 35128, Padua, Italy

    C. Foresta, N. Caretta & M. Rossato

  2. Department of Internal Medicine, University of Roma “Tor Vergata”, Roma, Italy

    A. Aversa

  3. Department of Urology, University of Bari, Italy

    C. Bettocchi

  4. Andrology Unit, Department of Clinical Physiopathology, University of Florence, Italy

    G. Corona

  5. Department of Medical Physiopathology, University of Roma “La Sapienza”, Roma, Italy

    S. Mariani

Authors
  1. C. Foresta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Caretta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Aversa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Bettocchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. Corona
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. Mariani
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Rossato
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Foresta.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Foresta, C., Caretta, N., Aversa, A. et al. Erectile dysfunction: symptom or disease?. J Endocrinol Invest 27, 80–95 (2004). https://doi.org/10.1007/BF03350917

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03350917

Key-words

Search

Navigation